XTX Topco Ltd Acquires Shares of 15,564 Prothena Co. plc (NASDAQ:PRTA)

XTX Topco Ltd acquired a new stake in shares of Prothena Co. plc (NASDAQ:PRTA) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 15,564 shares of the biotechnology company’s stock, valued at approximately $260,000.

Several other hedge funds have also recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in Prothena by 14.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock valued at $69,911,000 after acquiring an additional 539,359 shares during the last quarter. Armistice Capital LLC grew its position in shares of Prothena by 42.3% during the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company’s stock valued at $32,198,000 after purchasing an additional 464,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Prothena by 1,122.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after purchasing an additional 483,673 shares during the last quarter. Systematic Financial Management LP lifted its position in shares of Prothena by 25.8% in the second quarter. Systematic Financial Management LP now owns 193,763 shares of the biotechnology company’s stock worth $3,999,000 after buying an additional 39,771 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Prothena by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 165,423 shares of the biotechnology company’s stock valued at $3,414,000 after buying an additional 19,578 shares during the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on PRTA. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. Bank of America dropped their price objective on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating for the company in a research note on Tuesday, October 1st. Finally, HC Wainwright restated a “buy” rating and set a $84.00 target price on shares of Prothena in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.83.

Prothena Trading Down 14.9 %

PRTA stock opened at $11.95 on Thursday. The stock has a market cap of $643.02 million, a PE ratio of -4.82 and a beta of 0.09. Prothena Co. plc has a 12 month low of $11.70 and a 12 month high of $41.54. The company has a 50-day moving average price of $15.83 and a 200 day moving average price of $19.22.

Prothena (NASDAQ:PRTA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $1.22 million. During the same quarter in the prior year, the firm posted $0.38 earnings per share. The company’s quarterly revenue was down 98.9% on a year-over-year basis. Sell-side analysts forecast that Prothena Co. plc will post -2.24 EPS for the current year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.